Gibson Dunn Advises US WorldMeds on Acquisition of Adaptimmune Therapeutics’s TECELRA, lete-cel, afami-cel, and uza-cel Cell Therapies and Concurrent Financing
Dan Mulloy
Gibson Dunn is advising US WorldMeds, a specialty pharmaceutical company, on its acquisition of Adaptimmune Therapeutics’s TECELRA, lete-cel, afami-cel, and … The post Gibson Dunn Advises US WorldMeds on Acquisition of Adaptimmune Therapeutics’s TECELRA, lete-cel, afami-cel, and uza-cel Cell Therapies and Concurrent Financing appeared first on Gibson Dunn .